SEARCH

SEARCH BY CITATION

References

  • 1
    Liang MH, Fries JF: Containing costs in chronic disease monitoring strategies in the gold therapy of rheumatoid arthritis (editorial). J Rheumatol 5: 241244, 1978
  • 2
    Prashker MJ, Meenan RF: The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 38: 318325, 1995
  • 3
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39: 713722, 1996
  • 4
    Butt JH, Barthel JS, Moore RA: Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: natural history, symptomatology, and significance. Am J Med 84: 514, 1988
  • 5
    Langman MJS: Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 84: 1519, 1988
  • 6
    Corwin HL, Bonventre JV: Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am J Kidney Dis 4: 147152, 1984
  • 7
    Soll AH, Weinstein WM, Kurata J, McCarthy D: Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114: 307319, 1991
  • 8
    Furst DE: Are there differences among nonsteroidal anti-inflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal anti-inflammatory drugs Arthritis Rheum 37: 19, 1994
  • 9
    Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310: 563572, 1984
  • 10
    Blackshear JL, Napier JS, Davidman M, Stillman MT: Renal complications of nonsteroidal anti-inflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 14: 163175, 1985
  • 11
    Bender WL, Whelton A, Beschorner WE, Darwish MO, Hall-Craggs M, Solez K: Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Am J Med 76: 10061012, 1984
  • 12
    Murray MD, Brater DC: Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 112: 559560, 1990
  • 13
    Paulus HE: FDA Arthritis Advisory Committee Meeting: risks of agranulocytosis/aplastic anemia, flank pain, and adverse gastrointestinal effects with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 30: 593595, 1987
  • 14
    Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 331: 16751679, 1994
  • 15
    Ronco PM, Flahault A: Drug-induced end-stage renal disease (editorial). N Engl J Med 331: 17111712, 1994
  • 16
    Sandler DP, Burr FR, Weinberg CR: Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115: 165172, 1991
  • 17
    Wagner EH: Nonsteroidal anti-inflammatory drugs and renal disease-still unsettled (editorial). Ann Intern Med 115: 227228, 1991
  • 18
    Benson GD: Hepatotoxicity following the therapeutic use of antipyretic analgesics. Am J Med 85: 8593, 1983
  • 19
    Fries JF: Assessing and understanding patient risk. Scand J Rheumatol 92: 2124, 1992
  • 20
    Silverstein FE, Graham DY, Serior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 123: 241249, 1995
  • 21
    Levine JS: Misoprostol and non-steroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs. Ann Intern Med 123: 309310, 1995
  • 22
    Roth SH: Efficacy of antacid therapy for NSAID-induced symptomatic gastropathy. Practical Gastroenterol 18: 1420, 1994
  • 23
    Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA: Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug induced gastriculcer: a randomized, controlled trial. Ann Intern Med 115: 195200, 1991
  • 24
    Robinson MG, Griffin JW, Bowers J, Kogan FJ, Kogut DG, Lanza FL: Effect on ranitidine on gastro-duodenal mucosal damage induced by non-steroidal anti-inflammatory drugs. Dig Dis Sci 34: 424428, 1989
  • 25
    Walker AM, Bortnichak EA, Lanza L, Yood RA: The infrequency of liver function testing in patients using nonsteroidal antiinflammatory drugs. Arch Fam Med 4: 2429, 1995
  • 26
    Bernstein HN: Ocular safety of hydroxychloroquine sulfate (plaquenil). Ann Ophthalmol 23: 292296, 1991
  • 27
    Easterbrook M: Ocular effects and safety of antimalarial agents. Am J Med 85: 2329, 1988
  • 28
    Easterbrook M: The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23: 6267, 1993
  • 29
    Rynes RI: Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 84: 3539, 1983
  • 30
    Spalton DJ, Roe GMV, Hughes GRV: Hydroxychloroquine, dosage parameters and retinopathy. Lupus 2: 355358, 1993
  • 31
    Yancey C, White P: Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 92: 295296, 1993
  • 32
    Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33: 14491461, 1990
  • 33
    Mills PV, Beck M, Power BJ: Assessment of the retinal toxicity of hydroxychloroquine. Trans Opthalmol Soc UK 101: 109113, 1983
  • 34
    Mackenzie AH: Dose refinements in long term therapy of rheumatoid arthritis with antimalarials. Am J Med 75 (Suppl 1A): 4045, 1983
  • 35
    Easterbrook M: The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 91: 13681372, 1984
  • 36
    Day RD: Sulfasalazine. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 37
    Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B: Sulfasalazine for rheumatoid arthritis: toxicity for 774 patients monitored for 1 to 11 years. BMJ 293: 420423, 1986
  • 38
    Keisu M, Ekman E: Sulfasalazine associated agranulocytosis in Sweden 1972–1989. Eur J Clin Pharmacol 43: 215218, 1992
  • 39
    Toovey S, Hudson E, Hendry WF, Levi AJ: Sulfasalazine and male infertility: reversibility and possible mechanism. Gut 22: 445451, 1981
  • 40
    Birnie GG, McLoed TI, Watkinson G: Incidence of sulfasalazine-induced male infertility. Gut 22: 452455, 1981
  • 41
    Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, Lee RG, Weinblatt ME: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36: 329335, 1993
  • 42
    Weinblatt ME: Methotrexate. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 43
    Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37: 316328, 1994
  • 44
    Bergquist SR, Felson DT, Prashker MJ, Freedberg KA: The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 38: 326333, 1995
  • 45
    Weinblatt ME, Fraser P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32: 15921596, 1989
  • 46
    Weinblatt ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 12 (Suppl 12): 3539, 1985
  • 47
    Golden MR, Katz RS, Balk RA, Golden HE: The relationship of pre-existing lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 22: 10431047, 1995
  • 48
    Campbell PM, Wilske K, The Committee on Rheumatologic Care: Drug monitoring. In, Guidelines for Reviewers of Rheumatic Disease Care. Atlanta, American College of Rheumatology, 1989
  • 49
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 918, 1990
  • 50
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 121: 833841, 1994
  • 51
    Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellman DB: Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 18: 88110, 1988
  • 52
    Lederle Laboratories Division, American Cyanamid Company. Package insert for Rheumatrex, 1991
  • 53
    Ellman MH, Hurwitz H, Thomas C, Kozloff M: Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18: 17411743, 1991
  • 54
    Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 13171321, 1993
  • 55
    Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS: Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19: 14621465, 1992
  • 56
    Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS: Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99: 276281, 1995
  • 57
    Lockie LM, Smith DM: Forty-seven years experience with gold therapy in 1019 rheumatoid arthritis patients. Semin Arthritis Rheum 14: 238246, 1985
  • 58
    Davis P, Hughes GRV: Significance of eosinophilia during gold therapy. Arthritis Rheum 17: 964968, 1974
  • 59
    Gerber RC, Paulus HE: Gold therapy. Rheum Dis Clin North Am 1: 307318, 1975
  • 60
    Gordon DA: Gold compounds in the rheumatic diseases. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 61
    Jaffe IA: Penicillamine. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 62
    Singh G, Fries JF, Spitz P, Williams CA: Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 32: 837843, 1989
  • 63
    US Preventive Services Task Force: Guide to Clinical Preventive Services: Assessment of the Effectiveness of 169 Interventions. Edited by MFisher. Baltimore, Williams and Wilkins, 1989
  • 64
    Fauci CS, Young KR: Immunoregulatory agents. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 65
    Briggs GG, Freeman RK, Yaffe SJ: Drugs in pregnancy and lactation. Fourth edition. Baltimore, Williams and Wilkins, 1994
  • 66
    Needs CJ, Brooks PM: Antirheumatic medication during lactation. Br J Rheumatol 24: 291297, 1985
  • 67
    Anderson PO: Drugs and breast feeding. In, Handbook of Clinical Drug Data. Seventh edition. Edited by JEKroben, POAnderson, WGTroutman, LJDavid. Hamilton, IL, Drug Intelligence Publications, 1993
  • 68
    Anderson AJ: Drugs in pregnancy. In, Handbook of Clinical Drug Data. Seventh edition. Edited by JEKroben, POAnderson, WGTroutman, LJDavid. Hamilton, IL, Drug Intelligence Publications, 1993